EP0259782B1 - Dérivés de naphtalène et de l'indane, médicaments contenant ces composés et leurs procédés de préparation - Google Patents
Dérivés de naphtalène et de l'indane, médicaments contenant ces composés et leurs procédés de préparation Download PDFInfo
- Publication number
- EP0259782B1 EP0259782B1 EP87112865A EP87112865A EP0259782B1 EP 0259782 B1 EP0259782 B1 EP 0259782B1 EP 87112865 A EP87112865 A EP 87112865A EP 87112865 A EP87112865 A EP 87112865A EP 0259782 B1 EP0259782 B1 EP 0259782B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- propyl
- dimethoxy
- ethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
- C07C49/423—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5304—Acyclic saturated phosphine oxides or thioxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- EP-A-0.177.960 already describes tetrahydronaphthalenes which are substituted in the 2-position by a hydroxyl group which is optionally substituted by an acyl radical. These compounds have a pronounced calcium-antagonistic effect and can therefore be used as medicaments, in particular for the control or prevention of angina pectoris, ischemia, arrhythmias and high blood pressure.
- the new naphthalene and indane derivatives of the formula their enantiomers have their diastereomers and acid addition salts thereof, particularly the physiologically acceptable acid addition salts with inorganic or organic acids, other valuable pharmacological properties, in particular a heart rate lowering effect, and a lowering effect on the 0 2 demand of the heart.
- the present invention thus relates to the new tetrahydronaphthalene and indane derivatives of the formula I above, their enantiomers, their diastereomers, their acid addition salts, in particular for pharmaceutical use, their physiologically tolerable acid addition salts with inorganic or organic acids, processes for their preparation and medicaments containing these compounds .
- n is the number 1 or 2
- n is the number 1 or 2
- A is a carbonyl group and R 7 is a hydrogen atom or
- the new compounds are obtained by the following processes:
- the reaction is advantageously carried out in a solvent or solvent mixture such as acetone, diethyl ether, methylformamide, dimethylformamide, dimethyl sulfoxide, benzene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran, dioxane or in an excess of the compounds of the formulas II and / or III used and, if appropriate, in the presence of one Acid-binding agents, for example an alcoholate such as potassium tert-butoxide, an alkali metal hydroxide such as sodium or potassium hydroxide, an alkali metal carbonate such as potassium carbonate, an alkali metal amide such as sodium amide, an alkali metal hydride such as sodium hydride, a tertiary organic base such as triethylamine or pyridine, the latter at the same time can serve as a solvent, or a reaction accelerator such as potassium iodide, depending on the reactivity of the nucleophil
- the reaction is advantageously carried out in a solvent or solvent mixture such as acetone, diethyl ether, methylformamide, dimethylformamide, dimethyl sulfoxide, benzene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran, dioxane or in an excess of the compounds of the formulas IV and / or V and, if appropriate, in the presence of a Acid-binding agents, for example an alcoholate such as potassium tert-butoxide, an alkali metal hydroxide such as sodium or potassium hydroxide, an alkali metal carbonate such as potassium carbonate, an alkali metal amide such as sodium amide, an alkali metal hydride such as sodium hydride, a tertiary organic base such as triethylamine or pyridine, the latter at the same time can serve as a solvent, or a reaction accelerator such as potassium iodide, depending on the reactivity of the nucleophil
- the reduction is preferably carried out with a metal hydride such as lithium aluminum hydride or diborane or with a complex of borane and a thioether, for example with borane-dimethyl sulfide complex, optionally in the presence of a Lewis acid such as boron trifluoride in a suitable solvent such as diethyl ether or tetrahydrofuran at temperatures between 0 and 80 ° C, but preferably at the boiling point of the solvent used, for example at temperatures between 35 and 65 ° C.
- a metal hydride such as lithium aluminum hydride or diborane or with a complex of borane and a thioether, for example with borane-dimethyl sulfide complex
- a Lewis acid such as boron trifluoride
- suitable solvent such as diethyl ether or tetrahydrofuran
- a 2 in a compound of formula VI used is a carbonyl group or R 8 is a hydroxyl group
- the reduction is preferably carried out in the presence of a Lewis acid, for example with borane, for the preparation of compounds of formula I in which R 8 represents a hydrogen atom.
- a Lewis acid for example with borane
- a 2 in a compound of formula VI used is the carbonyl group or R B is a hydroxyl group
- the reduction is preferably carried out with lithium aluminum hydride in order to prepare compounds of the general formula I in which R 8 is a hydroxyl group.
- the oxidation is preferably carried out with an oxidizing agent such as potassium permanganate, barium manganate, potassium dichromate or with a ketone in the presence of a base (Oppenauer method), for example with acetone / aluminum isopropylate or benzophenone / potassium tert-butoxide, in a suitable solvent such as water, water / Dioxane, glacial acetic acid, water / acetic acid or toluene at temperatures between 0 and 150 ° C.
- the oxidation with an inorganic oxidizing agent is preferably carried out at temperatures between 0 and 50 ° C. and the oxidation according to Oppenauer preferably at the boiling point of the reaction mixture, for example at temperatures between 50 and 115 ° C.
- R 4 is an alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, bis (alkylsulfonyl) amino, N-alkylalkylsulfonylamino, alkylmercapto, alkoxy , Alkoxycarbonyloxy, hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, phenylalkoxy, trifluoromethoxy, difluoromethoxy, cyanoalkoxy, alkylsulfonyloxy or trifluoromethylsulfonyloxy group:
- R 10 represents an alkyl, alkanoyl, alkoxycarbonyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, alkylsulfonyl, phenylalkyl, trifluoromethyl, difluoromethyl or cyanoalkyl group, the alkyl and alkoxy parts mentioned above each having 1 to 3 carbon atoms or the alkanoyl part May contain 2 or 3 carbon atoms.
- reaction is advantageously carried out in a solvent or solvent mixture such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or dimethylformamide, optionally also in the presence of an acid-activating agent or a dehydrating agent, for.
- a solvent or solvent mixture such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or dimethylformamide, optionally also in the presence of an acid-activating agent or a dehydrating agent, for.
- any reactive groups present such as hydroxyl, amino or imino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.
- the trimethylsilyl, acetyl, benzoyl, benzoyl or tetrahydropyranyl group comes as a protective radical for a hydroxyl group
- the protective radical for an imino or amino group is the acetyl, benzoyl, ethoxycarbonyl or benzyl group.
- the optional subsequent removal of a protective radical used is preferably carried out hydrolytically in an aqueous solvent, for example in water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 ° C, preferably at the boiling point of the reaction mixture.
- an aqueous solvent for example in water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 ° C, preferably at the boiling point of the reaction mixture.
- a benzyl radical is preferably split off hydrogenolytically, for example using hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50 ° C., but preferably at Room temperature, and a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
- a catalyst such as palladium / carbon
- a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid
- an acid such as hydrochloric acid
- the subsequent debenzylation is preferably carried out in a solvent such as water, water / ethanol, methanol, glacial acetic acid, ethyl acetate or dimethylformamide with hydrogen in the presence of a hydrogenation catalyst such as Raney nickel, platinum or palladium / carbon at temperatures between 0 and 50 ° C., preferably however carried out at room temperature.
- a hydrogenation catalyst such as Raney nickel, platinum or palladium / carbon at temperatures between 0 and 50 ° C., preferably however carried out at room temperature.
- the compounds of formula I obtained can be separated into their diastereomers, for example by column chromatography, and into their enantiomers, for example by column chromatography on a chiral phase or by crystallization with optically active acids, e.g. with D- or L-monomethyltartaric acid, D- or L-diacetyi tartaric acid, D- or L-tartaric acid, D- or L-lactic acid, D- or L-camphoric acid, D- or L-dibenzoyltartaric acid, D- or L-camphorsulfonic acid or D- or L-camphanic acid.
- optically active acids e.g. with D- or L-monomethyltartaric acid, D- or L-diacetyi tartaric acid, D- or L-tartaric acid, D- or L-lactic acid, D- or L-camphoric acid, D- or L-dibenzoyltartaric acid, D- or L-camphors
- the compounds of formula 1 obtained can also be converted into their acid addition salts, in particular for their pharmaceutical use, into their physiologically compatible acid addition salts with inorganic or organic acids.
- suitable acids here are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, lactic acid, citric acid, tartaric acid, succinic acid, maleic acid, fumaric acid or oxalic acid.
- a starting compound of the formula IV is obtained, for example, by reacting a carboxylic acid of the formula XI with a corresponding amine in the presence of N, N'-carbonyl-dilmidazole and then reducing the amide thus obtained.
- a compound of the formulas VI, VII, VIII and X used as starting material is obtained by reacting a corresponding ⁇ -halogen compound with a corresponding amine.
- the new compounds of the formula and their physiologically tolerable acid addition salts with inorganic or organic acids have valuable pharmacological properties, in particular in the case of minor central side effects, a particularly heart rate-lowering effect and a reduction in the 02 requirement of the heart.
- the effect of the substances to be examined on the heart rate was examined per dose in 2 rats with an average weight of 250-300 g.
- the rats were anesthetized with pentobarbital (50 mg / kg i.p. and 10 mg / kg s.c.).
- pentobarbital 50 mg / kg i.p. and 10 mg / kg s.c.
- the substances to be examined were injected into the jugular vein in aqueous solution (0.1 ml / 100 g).
- the blood pressure was measured via a cannula embedded in a carotid artery and the heart rate was recorded from an EKG (11th or III. Lead) derived with needle electrodes.
- the heart rate of the animals in the control period was between 350 and 400 beats / minutes (bpm).
- the compounds produced according to the invention have no toxic side effects in therapeutic doses. For example, with intravenous application of substances A and C even in a high dose of 10 mg / kg to mice, apart from a small sedation, no toxic side effects were observed.
- the compounds produced according to the invention are suitable for the treatment of sinus tachycardias of various origins and for the prophylaxis and therapy of ischemic heart diseases.
- the dosage required to achieve a corresponding effect is expediently once or twice a day 0.03 to 0.4 mg / kg body weight, preferably 0.07 to 0.25 mg / kg body weight.
- the active ingredient, corn starch, milk sugar and polyvinylpyrrolidone are mixed well and moistened with water.
- the moist mass is pressed through a sieve with a 1 mm mesh size, dried at approx. 45 ° C and then the granules are passed through the same sieve.
- domed dragee cores with a diameter of 6 mm are pressed on a tablet machine.
- the dragee cores thus produced are coated in a known manner with a layer consisting essentially of sugar and talc.
- the finished coated tablets are polished with wax. Drage weight: 130 mg
- the active substance is dissolved in water for injection purposes in a suitable preparation vessel and the solution is made isotonic with sorbitol.
- the solution After filtration through a membrane filter, the solution is poured into cleaned and sterilized ampoules with N 2 gassing and autoclaved in flowing steam for 20 minutes.
- the hard fat is melted.
- the ground active substance is homogeneously dispersed in the melt at 38 ° C. It is cooled to 35 ° C and poured into weakly pre-cooled suppository molds.
- Dest. Water is heated to 70 ° C. Hydroxyethyl cellulose, benzoic acid and tartaric acid are dissolved therein with stirring. It is cooled to room temperature and the glycerin and the sorbitol solution are added with stirring. The active ingredient is added at room temperature and stirred until completely dissolved. Subsequently, the juice is evacuated with stirring.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Feedback Control In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT87112865T ATE59378T1 (de) | 1986-09-11 | 1987-09-03 | Neue naphtalin- und indanderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863630903 DE3630903A1 (de) | 1986-09-11 | 1986-09-11 | Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel |
DE3630903 | 1986-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0259782A1 EP0259782A1 (fr) | 1988-03-16 |
EP0259782B1 true EP0259782B1 (fr) | 1990-12-27 |
Family
ID=6309344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87112865A Expired - Lifetime EP0259782B1 (fr) | 1986-09-11 | 1987-09-03 | Dérivés de naphtalène et de l'indane, médicaments contenant ces composés et leurs procédés de préparation |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0259782B1 (fr) |
JP (1) | JPS6377842A (fr) |
KR (1) | KR880003889A (fr) |
AT (1) | ATE59378T1 (fr) |
AU (1) | AU597719B2 (fr) |
DD (1) | DD263525A5 (fr) |
DE (2) | DE3630903A1 (fr) |
DK (1) | DK472387A (fr) |
FI (1) | FI873917A (fr) |
HU (1) | HU206077B (fr) |
IL (1) | IL83850A (fr) |
NO (1) | NO166528C (fr) |
NZ (1) | NZ221766A (fr) |
PH (1) | PH25680A (fr) |
PT (1) | PT85689B (fr) |
ZA (1) | ZA876768B (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338793A2 (fr) * | 1988-04-20 | 1989-10-25 | The Wellcome Foundation Limited | Sulfonanilides antihypertensifs |
EP0361577A1 (fr) * | 1988-09-19 | 1990-04-04 | Akzo N.V. | Dérivés de tétrahydronaphthalène et indane |
US5166209A (en) * | 1989-04-21 | 1992-11-24 | Burroughs Wellcome Co. | Pharmacologically active compounds |
US5180746A (en) * | 1989-02-17 | 1993-01-19 | Takeda Chemical Industries, Ltd. | Aralkylamine compounds |
WO1995007075A1 (fr) * | 1993-09-09 | 1995-03-16 | Synaptic Pharmaceutical Corporation | Nouveaux derives d'amine aromatique |
US5643784A (en) * | 1990-12-04 | 1997-07-01 | H, Lundbeck A/S | Indan derivatives |
US5658921A (en) * | 1992-06-12 | 1997-08-19 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US5807871A (en) * | 1991-06-13 | 1998-09-15 | H. Lundbeck A/S | Piperidine derivatives having anxiolytic effect |
US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103745D0 (sv) * | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
JPH09502193A (ja) * | 1993-09-09 | 1997-03-04 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 抗高血糖症および/または抗肥満症活性を有するホスフィン酸誘導体 |
CA2276278C (fr) | 1997-02-27 | 2009-04-07 | Takeda Chemical Industries, Ltd. | Composes du type amine, et methode de production et utilisation connexes |
AU2001244700A1 (en) | 2000-04-03 | 2001-10-15 | Takeda Chemical Industries Ltd. | Process for producing amine derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS159795B2 (fr) * | 1971-04-19 | 1975-01-31 | ||
CH654294A5 (it) * | 1982-07-09 | 1986-02-14 | Yason Srl | Composti ad attivita bloccante del calcio a livello cardiaco e cerebrale, metodo per la loro preparazione e composizioni farmaceutiche. |
NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
DK691488A (da) * | 1987-12-14 | 1989-06-15 | Beecham Group Plc | Hidtil ukendte forbindelser |
-
1986
- 1986-09-11 DE DE19863630903 patent/DE3630903A1/de not_active Withdrawn
-
1987
- 1987-09-03 DE DE8787112865T patent/DE3767094D1/de not_active Expired - Fee Related
- 1987-09-03 EP EP87112865A patent/EP0259782B1/fr not_active Expired - Lifetime
- 1987-09-03 AT AT87112865T patent/ATE59378T1/de not_active IP Right Cessation
- 1987-09-09 DD DD87306821A patent/DD263525A5/de not_active IP Right Cessation
- 1987-09-09 NZ NZ221766A patent/NZ221766A/xx unknown
- 1987-09-10 HU HU874035A patent/HU206077B/hu unknown
- 1987-09-10 JP JP62227532A patent/JPS6377842A/ja active Pending
- 1987-09-10 FI FI873917A patent/FI873917A/fi not_active IP Right Cessation
- 1987-09-10 KR KR870010008A patent/KR880003889A/ko not_active Application Discontinuation
- 1987-09-10 PH PH35795A patent/PH25680A/en unknown
- 1987-09-10 IL IL83850A patent/IL83850A/xx not_active IP Right Cessation
- 1987-09-10 ZA ZA876768A patent/ZA876768B/xx unknown
- 1987-09-10 NO NO873784A patent/NO166528C/no unknown
- 1987-09-10 DK DK472387A patent/DK472387A/da not_active Application Discontinuation
- 1987-09-11 AU AU78297/87A patent/AU597719B2/en not_active Ceased
- 1987-09-11 PT PT85689A patent/PT85689B/pt not_active IP Right Cessation
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338793A2 (fr) * | 1988-04-20 | 1989-10-25 | The Wellcome Foundation Limited | Sulfonanilides antihypertensifs |
EP0338793A3 (fr) * | 1988-04-20 | 1991-01-02 | The Wellcome Foundation Limited | Sulfonanilides antihypertensifs |
EP0361577A1 (fr) * | 1988-09-19 | 1990-04-04 | Akzo N.V. | Dérivés de tétrahydronaphthalène et indane |
US4980354A (en) * | 1988-09-19 | 1990-12-25 | Akzo N.V. | Tetrahydronaphthalene and indane derivatives |
US5180746A (en) * | 1989-02-17 | 1993-01-19 | Takeda Chemical Industries, Ltd. | Aralkylamine compounds |
US5166209A (en) * | 1989-04-21 | 1992-11-24 | Burroughs Wellcome Co. | Pharmacologically active compounds |
US5643784A (en) * | 1990-12-04 | 1997-07-01 | H, Lundbeck A/S | Indan derivatives |
US5807871A (en) * | 1991-06-13 | 1998-09-15 | H. Lundbeck A/S | Piperidine derivatives having anxiolytic effect |
US6031099A (en) * | 1991-06-13 | 2000-02-29 | H. Lundbeck A/S | Piperidine derivates having anxiolytic effect |
US6207677B1 (en) | 1991-06-13 | 2001-03-27 | H. Lundbeck A/S | Piperidine derivatives having anxiolytic effect |
US5658921A (en) * | 1992-06-12 | 1997-08-19 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US5684012A (en) * | 1992-06-12 | 1997-11-04 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US5830896A (en) * | 1992-06-12 | 1998-11-03 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US5837707A (en) * | 1992-06-12 | 1998-11-17 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US6090808A (en) * | 1992-06-12 | 2000-07-18 | H. Lundbeck A/S | Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
US5508306A (en) * | 1992-11-13 | 1996-04-16 | Synaptic Pharmaceutical Corporation | Aromatic amine derivatives |
WO1995007075A1 (fr) * | 1993-09-09 | 1995-03-16 | Synaptic Pharmaceutical Corporation | Nouveaux derives d'amine aromatique |
US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
Also Published As
Publication number | Publication date |
---|---|
PH25680A (en) | 1991-09-04 |
HU206077B (en) | 1992-08-28 |
DE3767094D1 (de) | 1991-02-07 |
NO166528B (no) | 1991-04-29 |
NO166528C (no) | 1991-08-07 |
EP0259782A1 (fr) | 1988-03-16 |
DK472387A (da) | 1988-03-12 |
PT85689B (pt) | 1990-06-29 |
PT85689A (de) | 1987-10-01 |
KR880003889A (ko) | 1988-05-30 |
AU7829787A (en) | 1988-03-17 |
DK472387D0 (da) | 1987-09-10 |
IL83850A (en) | 1991-09-16 |
DE3630903A1 (de) | 1988-03-24 |
JPS6377842A (ja) | 1988-04-08 |
FI873917A (fi) | 1988-03-12 |
HUT46885A (en) | 1988-12-28 |
AU597719B2 (en) | 1990-06-07 |
ZA876768B (en) | 1989-05-30 |
DD263525A5 (de) | 1989-01-04 |
NO873784D0 (no) | 1987-09-10 |
FI873917A0 (fi) | 1987-09-10 |
NZ221766A (en) | 1989-05-29 |
NO873784L (no) | 1988-03-14 |
ATE59378T1 (de) | 1991-01-15 |
IL83850A0 (en) | 1988-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0242518B1 (fr) | Cycloalcano[1,2-b]indole-sulfonamides | |
EP0270947B1 (fr) | 2-Aminotétralines basiques substitués | |
EP0161604A2 (fr) | Dérivés d'aminotétraline, médicaments contenant ces composés et procédé pour leur préparation | |
EP0292840B1 (fr) | Dérivés d'amines cycliques, médicaments le contenant et procédé de leur préparation | |
EP0259782B1 (fr) | Dérivés de naphtalène et de l'indane, médicaments contenant ces composés et leurs procédés de préparation | |
WO1998037061A1 (fr) | Arylsulfonamides et leurs analogues, et procedes d'utilisation desdites substances pour traiter les maladies neurodegeneratives | |
EP0090362A2 (fr) | Dérivés des acides cycloalka(c)pyrrol carboxyliques, leur procédé de préparation, les agents les contenant, leur emploi, les acides cycloalka(c)pyrrol carboxyliques comme intermédiaires et leur procédé de préparation | |
EP0204349A2 (fr) | Dérivés d'amines hétéroaromatiques, médicaments les contenant et procédé pour leur préparation | |
EP0109020A2 (fr) | Dérivés d'amino-acides tricycliques, leur procédé de préparation, les composés les contenant, leur emploi, et les amino-acides bicycliques comme intermédiaires et leur procédé de préparation | |
WO1993004035A1 (fr) | Nouveaux derives 3,5-di-tert.butyl-4-hydroxyphenyles, leur procede de fabrication et medicaments les renfermant | |
EP0157267B1 (fr) | Benzopyrannes substiués, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0161599A2 (fr) | Dérivés de benzazépine, médicaments contenant les composés et procédé pour leur préparation | |
DE3146623A1 (de) | "neue phenylalkylamine, ihre herstellung und ihre verwendung als arzneimittel" | |
EP0332064A2 (fr) | Dérivés du benzocycloheptène, médicament contenant ces composés et procédé de leur préparation | |
EP0082461B1 (fr) | Phénoxyalcanolamines et phénoxyalcanol-cycloalcoylamines substituées, procédé pour leur préparation, compositions pharmaceutiques contenant ces composés et intermédiaires | |
DE3320394A1 (de) | Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung | |
EP0491263B1 (fr) | Composés phénylalkylaminoalkyliques, procédé pour leur préparation et compositions pharmaceutiques qui les contiennent | |
EP0262395A2 (fr) | Composés sulfonamido-éthyliques, médicaments les contenant et leur procédé de préparation | |
EP0224794A2 (fr) | Dérivés amines cycliques, médicaments contenant ces composés et leur procédé de préparation | |
DE10015866A1 (de) | Aryl- und Heteroarylsulfonate | |
EP0175249A2 (fr) | Dérivés de phénylacétonitrile | |
EP0113880A2 (fr) | Derivés de 2-azabicyclo(2.2.1)heptane, leur procédé de préparation, les composés les contentant et leur emploi, de même que les dérivés de 2-azabicyclo(2.2.1)heptane comme intermédiaires et leur procédé de préparation | |
DE2834107A1 (de) | Benzylalkoholderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel | |
EP0723969A1 (fr) | Dérivés de l'acide phosphonocarboxylique et leur utilisation dans le traitement de maladies dégénératives des articulations | |
EP0146787A2 (fr) | Dérivés d'indole, médicaments contenant ces composés et procédé pour leur preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19880818 |
|
17Q | First examination report despatched |
Effective date: 19890609 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT Effective date: 19901227 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19901227 Ref country code: SE Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19901227 Ref country code: NL Effective date: 19901227 |
|
REF | Corresponds to: |
Ref document number: 59378 Country of ref document: AT Date of ref document: 19910115 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3767094 Country of ref document: DE Date of ref document: 19910207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19910407 |
|
ET | Fr: translation filed | ||
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) | ||
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19910809 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19910812 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19910814 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19910821 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19910927 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19910928 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19911030 Year of fee payment: 5 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EPTA | Lu: last paid annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19920903 Ref country code: GB Effective date: 19920903 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19920903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19920930 Ref country code: BE Effective date: 19920930 Ref country code: CH Effective date: 19920930 |
|
K2C3 | Correction of patent specification (complete document) published |
Effective date: 19901227 |
|
BERE | Be: lapsed |
Owner name: KARL THOMAE G.M.B.H. Effective date: 19920930 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19920903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19930528 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19930602 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |